Visit PracticeUpdate.com for free access to medical journal scans, expert insights and commentaries on the latest breakthroughs, conference coverage, and crucial practice-relevant information from top experts in your field. Daily updates on topics including: Try it today for free at PracticeUpdate.com BENIGN HEMATOLOGY DIABETES PRIMARY CARE CARDIOLOGY EYE CARE ONCOLOGY CLINICAL DENTISTRY GASTROENTEROLOGY RESPIRATORY MEDICINE DERMATOLOGY NEUROLOGY UROLOGY
September 6-9, 2023 Hybrid Event soho.click/2023 SOCIETY OF HEMATOLOGIC ONCOLOGY ELEVENTH ANNUAL MEETING • HYBRID EVENT TO DOWNLOAD THE MOBILE APP, GO TO: https://soho.click/app GO TO MOBILE APP To participate in Q&A and polls, create custom schedules, view slides, posters, speaker info and more, download the mobile app. The SOHO 2023 mobile app is available as a free download in native formats for android and apple as well as for computer viewing.
ISSN 2152-2650 Volume 1 No. 1 January 2023 CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA The Official Journal of the International Myeloma Society The Official Journal of the Society of Hematologic Oncology An Official Journal of the European Society for Medical Oncology Proceedings of the Society of Hematologic Oncology 2023 Annual Meeting In This Supplement Volume 23 Supplement 1 September 2023
Integrate world-class, evidence-based content into your care process, making it accessible to providers and patients where and when they need it. • Clinical Pathways • Advanced Clinical Decision Support • Patient Engagement • Learning & Competency Management • Clinical Reference Empower better decisions throughout the patient journey Learn more about our solutions today. Visit Elsevier.com/clinical-solutions.
soho.click/2023 Society of Hematologic Oncology Eleventh Annual Meeting September 6–9, 2023 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Organizing Committees SOHO Board of Directors Jennifer Brown, MD, PhD, President & Chairperson of the Board Guillermo Garcia-Manero, MD, President-Elect Moshe Talpaz, MD, Immediate Past President Susan M. O’Brien, MD, Past President Hagop Kantarjian, MD, Secretary Anthony H. Goldstone, CBE, FRCP, Past President Dieter Hoelzer, MD, PhD, Past President Alan List, MD, Past President Sagar Lonial, MD, FACP, Past President Ching-Hon Pui, MD, Past President Julie Vose, MD, Board Member Janet Cesak, MBA, BS, Managing Director SOHO Steering Committee Hagop Kantarjian, MD, Chair Elias Anaissie, MD Renier Brentjens, MD, PhD Jennifer Brown, MD, PhD Sabina Chiaretti, MD, PhD Florence Cymbalista, MD, PhD Claire Dearden, MD, FRCP, FRCPath John DiPersio, MD, PhD Guillermo Garcia-Manero, MD Sergio Giralt, MD Anthony Goldstone, CBE, FRCP Claire Harrison, DM, FRCP Dieter Hoelzer, MD, PhD Timothy Hughes, MD, MBBS Sundar Jagannath, MD Rami Komrokji, MD Jeffrey Lancet, MD Suzanne Lentzsch, MD, PhD Alan List, MD Sagar Lonial, MD, FACP Selina Luger, MD Thomas Martin, MD María-Victoria Mateos, MD, PhD Emili Montserrat, MD Carol Moreno, MD, PhD Alison Moskowitz, MD Charles Mullighan, MBBS (Hons), MSc, MD Susan O’Brien, MD Ryuzo Ohno, MD Ching-Hon Pui, MD Paul Richardson, MD Valeria Santini, MD Phillip Scheinberg, MD David Scheinberg, MD, PhD John Seymour, MBBS, FRACP, PhD Elizabeth Shpall, MD Eric L. Smith Wendy Stock, MD Richard Stone, MD Moshe Talpaz, MD Ayalew Tefferi, MD Julie Vose, MD
SOHO Education Committee Sagar Lonial, MD, FACP, Chair Guillermo Garcia-Manero, MD, Subcommittee Chair Sergio Giralt, MD, Subcommittee Chair Jeff H. Lipton, PHD MD, Subcommittee Chair Selina Luger, MD, Subcommittee Chair Thomas Martin, MD, Subcommittee Chair Susan O’Brien, MD, Subcommittee Chair Farhad Ravandi, MD, Subcommittee Chair Laurie Sehn, MD, MPH, Subcommittee Chair Srdan Verstovsek, MD, PhD, Subcommittee Chair Pamela Allen, MD, MSc Michael Andreeff, MD, PhD Stephen Ansell, MD, PhD Catherine Bollard, MD, MBChB Renier Brentjens, MD, PhD Jennifer Brown, MD, PhD Sylvie Castaigne, MD Jorge Cortés, MD Nick Cross, MA, PhD, FRCPath Florence Cymbalista, MD, PhD Naval Daver, MD Daniel DeAngelo, MD Michael Deininger, MD, PhD Meletios Dimopoulos, MD Angela Dispenzieri, MD Hervé Dombret, MD Barbara Eichhorst, MD Pierre Fenaux, MD Alessandra Ferrajoli, MD Nathan Fowler, MD Paolo Ghia, MD Lucy Godley, MD, PhD Damian Green, MD Alex Herrera, MD Dieter Hoelzer, MD, PhD Timothy Hughes, MD, MBBS Elias Jabbour, MD Joseph Jurcic, MD Brad Kahl, MD Partow Kebriaei, MD Thomas Kipps, MD, PhD Rami Komrokji, MD Jeffrey Lancet, MD Mary Jo Lechowicz, MD Suzanne Lentzsch, MD, PhD Georg Lenz, MD, PhD Bob Löwenberg, MD Matthew Lunning, DO Kami J. Maddocks, MD John O. Mascarenhas, MD Marcela V. Maus, MD, PhD Laura Michaelis, MD Mohamad Mohty, MD Emili Montserrat, MD Franck Morschhauser, MD, PhD Alison Moskowitz, MD Lori Muffly, MD Owen O’Connor, MD, PhD Robert Orlowski, MD, PhD Prof. Francesco Passamonti, MD Uwe Platzbecker, MD Barbara Pro, MD Ching-Hon Pui, MD John Radford, MD Jerald Radich, MD Delphine Rea, MD, PhD Katy Rezvani, MD, PhD Josep-Maria Ribera, MD, PhD Gail J. Roboz, MD Valeria Santini, MD Kerry Savage, MD Richard Schlenk, MD, PhD John Seymour, MBBS, FRACP, PhD Bijal Shah, MD Eric Smith, MD PhD Simona Soverini, PhD John Welch, MD, PhD William Wierda, MD, PhD Thomas Witzig, MD Pier Luigi Zinzani, MD, PhD SOHO Publication Committee Sundar Jagannath, MD, Chair Brad S. Kahl, MD Hagop Kantarjian, MD Sagar Lonial, MD, FACP Moshe Talpaz, MD SOHO Scientific Committee Moshe Talpaz, MD, Chair Pamela Allen, MD, MSc Elias Anaissie, MD Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD Renier Brentjens, MD, PhD Hetty Carraway, MD, MBA Jorge Cortés, MD Florence Cymbalista, MD, PhD Naval Daver, MD Marco Davila, MD, PhD Michael Deininger, MD, PhD Courtney D. DiNardo, MD, MSCE Hervé Dombret, MD Barbara Eichhorst, MD
Pierre Fenaux, MD Guillermo Garcia-Manero, MD Andre Goy, MD, MS Dieter Hoelzer, MD, PhD Elias Jabbour, MD Sundar Jagannath, MD Tapan Kadia, MD Hagop Kantarjian, MD Partow Kebriaei, MD Eva Kimby, MD, PhD Rami Komrokji, MD Marina Konopleva, MD Mary Jo Lechowicz, MD Georg Lenz, MD, PhD Jeffrey M. Lipton, PhD, MD, FRCPC Alan List, MD Sagar Lonial, MD, FACP Thomas Martin, MD John O. Mascarenhas, MD Laura Michaelis, MD Carol Moreno, MD, PhD Ajay K. Nooka, MD, MPH, FACP Ryuzo Ohno, MD Eric Padron, MD Uday R. Popat, MD Barbara Pro, MD Ching-Hon Pui, MD Prof. Anne Quinquenel, MD, PhD John Radford, MD Jerald Radich, MD Farhad Ravandi, MD Gail J. Roboz, MD Giuseppe Saglio, MD Kerry Savage, MD Laurie Sehn, MD, MPH Mikkael A. Sekeres, MD Bijal Shah, MD Elizabeth Shpall, MD Simona Soverini, PhD Wendy Stock, MD Sarah K. Tasian, MD Ayalew Tefferi, MD Evangelos Terpos, MD, PhD Fritz Van Rhee, MD Julie Vose, MD Eunice S. Wang, MD Andrew Wei, MBBS, PhD William Wierda, MD, PhD Maurizio Zangari, MD Pier Luigi Zinzani, MD, PhD
Volume 23, Supplement 1 September 2023 CLINICAL LYMPHOMA, MYELOMA LEUKEMIA & Volume 23, Number 7 July 2023 Senior Editor-in-Chief Sundar Jagannath, MD New York, New York Editors-in-Chief Hagop Kantarjian, MD Houston, Texas Sagar Lonial, MD Atlanta, Georgia Brad Kahl, MD St. Louis, Missouri Associate Editors Jeremy Abramson, MD Boston, Massachusetts Martha Arellano, MD Atlanta, Georgia Paul M. Barr, MD Rochester, New York Ali Bazarbachi, MD Beirut, Lebanon Kristie A. Blum, MD Atlanta, Georgia Ajai Chari, MD, New York, USA Raymond Comenzo, MD Boston, Massachusetts Pierre Fenaux, MD, PhD Paris, France Guillermo Garcia-Manero, MD Houston, Texas Francesca Gay, MD, PhD Torino, Italy Morie Gertz, MD Rochester, Minnesota Armin Ghobadi, MD St. Louis, Missouri Wolfgang Hiddemann, MD, PhD Munich, Germany Dieter Hoelzer, MD, PhD Frankfurt, Germany Rami Komrokji, MD Tampa, Florida Amrita Krishnan, MD Duarte, California Peter Martin, MD New York, New York Susan O’Brien, MD Orange, California Enrique Ocio, MD, PhD Salamanca, Spain Ching-Hon Pui, MD Memphis, Tennessee JoséMaría Ribera, MD, PhD Barcelona, Spain Moshe Talpaz, MD Ann Arbor, Michigan Julie M. Vose, MD Omaha, Nebraska William G. Wierda, MD, PhD Houston, Texas Jasmine Zain, MD Duarte, California Editorial Board Anjali Advani Cleveland, Ohio Martha Arellano, MD Atlanta, Georgia Augustin Avilés, MD Col. Juárez, Mexico Hamdy F. Azim, MD Cairo, Egypt Stefan Barta, MD, MS, MRCP Philadelphia, Pennsylvania Rachid Baz, MD Tampa, Florida Ali Bazarbachi, MD, PhD New York, New York Meral M. Beksac, MD Ankara, Turkey James R. Berenson, MD West Hollywood, California Michael R. Bishop, MD Chicago, Illinois J. Magnus Björkholm, MD Stockholm, Sweden Joan Bladé, MD Barcelona, Spain Mario Boccadoro, MD Turin, Italy Prithviraj Bose, MD Houston, Texas Danielle Brander, MD Durham, North Carolina Paolo Caimi, MD Cleveland, Ohio Amanda Cashen, MD St. Louis, Missouri Franco Cavalli, MD Bellinzona, Switzerland Robert Chen, MD Duarte, California Jonathan Cohen, MD Atlanta, Georgia Gordon Cook, MD Leeds, United Kingdom Jan Cornelissen, MD Rotterdam, The Netherlands Naval G. Daver, MD Houston, Texas Catherine Diefenbach, MD New York, New York Meletios A. Dimopoulos, MD Athens, Greece Courtney DiNardo, MD Houston, Texas Martin Heinz Dreyling, MD München, Germany Hermann Einsele, MD Bavaria, Germany Ahmet Emre Eskazan, MD Fatih, Turkey Christopher Flowers, MD, MS Atlanta,Georgia James Foran, MD, FRCP Jacksonville, Florida Christian Gisselbrecht, MD Paris, France Anton Hagenbeek, MD Amsterdam, The Netherlands Mehdi Hamadani, MD Milwaukee, Wisconsin Alex Herrera, MD Duarte, California Carraway Hetty, MD Cleveland, Ohio Wolfgang Hiddemann, MD Munich, Germany Brian Hill, MD Cleveland, Ohio P. Joy Ho, MBBS Sydney, New South Wales Fangxin Hong, MD Boston, Massachusetts Steve Horwitz, MD New York, New York Tanin Intragumtornchai, MD Bangkok, Thailand Elias J. Jabbour, MD Houston, Texas Nitin Jain, MD Houston, Texas Sima Jeha, MD Memphis, Tennessee Douglas Joshua, MD Sydney, Australia Tapan M. Kadia, MD Houston, Texas Manali Kamdar, MD Aurora, Colorado Efstathios Kastritis, MD Athens, Greece Vaishalee Kenkre, MD Madison, Wisconsin Nadia Khan, MD Philadelphia, Pennsylvania Issa F. Khouri, MD Houston, Texas Rami Komrokji, MD Tampa, Florida Lale Kostakoglu, MD, MPH New York, New York Robert Kridel, MD, MPH, PhD Toronto, Ontario Daniel Landsburg, MD Philadelphia, Pennsylvania Matthew Lunning, DO Omaha, Nebraska Aaron Logan, MD, PhD San Francisco, California David Maloney, MD Seattle, Washington Peter McLaughlin, MD Houston, Texas Neha Mehta-Shah, MD St. Louis, Missouri Giampaolo Merlini, MD Pavia, Italy Roberto Mina, MD London, United Kingdom Philippe Moreau, MD Nantes, France Loretta Nastoupil, MD Houston, Texas Paola Neri, MD, PhD Calgary, Alberta Andrei A. Novik, MD, PhD St. Petersburg, Russia Gr zegor z Nowakowski, MD Rochester, Minnesota Steven Park, MD Concord, North Carolina Mrinal Patnaik, MD Rochester, Minnesota Charlotte Pawlyn, PhD London, United Kingdom Naveen Pemmaraju, MD Houston, United States Daniel Persky, MD Tucson, Arizona Tycel Phillips, MD Ann Arbor, Michigan Craig Portell, MD Charlottesville, Virginia Barbara Pro, MD Chicago, Illinois Pia Raanani, MD Petah Tikva, Israel Vincent Rajkumar, MD Rochester, Minnesota Farhad Ravandi, MD Houston, Texas Nishitha Reddy, MD Nashville, Tennessee Peter Riedell, MD Chicago, Illinois Gail J. Roboz, MD New York, New York Mark Roschewski, MD Bethesda, Maryland Philippe Rousselot, MD Le Chesnay, France Valeria Santini, MD Florence, Italy Phillip Scheinberg, MD Sao Paulo, Brazil John Seymour, MD Parkville, Australia Bijal Shah, MD Atlanta, Georgia Nina Shah, MD San Francisco, California Jamile Shammo, MD Chicago, Illinois Mitchell Smith, MD, PhD Washington, DC Index Medicus/PubMed (NLM), Journal Citation Reports/ Science Edition (Thomson ISI), Cambridge Scientific Abstracts (CSA/CIG), CINAHL: Cumulative Index to Nursing & Allied Health Literature (EBSCO), Current Contents ®/ Clinical Medicine (Thomson ISI), EMBASE/Excerpta Medica (Elsevier), Science Citation Index Expanded™ (Thomson ISI), Science Citation Index ® (Thomson ISI), SCOPUS (Elsevier), Web of Science ® (Thomson ISI)
Volume 23, Supplement 1 September 2023 CLINICAL LYMPHOMA, MYELOMA LEUKEMIA & Volume 23, Number 7 July 2023 Sonali M. Smith, MD Chicago, Illinois Pieter Sonneveld, MD Rotterdam, The Netherlands David Steensma, MD Boston, Massachusetts Richard Stone, MD Boston, Massachusetts Jakub Svoboda, MD Philadelphia, Pennsylvania Lode Swinnen, MD Baltimore, Maryland Constantine Tam, MD Victoria, Australia Philip A. Thompson, MB, BS Houston, Texas Kensei Tobinai, MD, PhD Tokyo, Japan Suzanne Trudel, MSc, MD Toronto, Ontario Eunice Wang, MD Buffalo, New York Nina Wagner-Johnston, MD Baltimore, Maryland Chng Wee Joo, MB ChB, PhD Singapore, Singapore Dennis Weisenburger, MD Omaha, Nebraska Agnieszka Wierzbowska, MD, PhD Lodz, Poland David T. Yang, MD Madison, Wisconsin Pier Luigi Zinzani, MD Bologna, Italy Emanuele Zucca, MD Bellinzona, Switzerland Clinical Lymphoma, Myeloma & Leukemia (ISSN 2152-2650) is published monthly by Elsevier, 230 Park Avenue, Suite 800, New York, NY 10169. POSTMASTER: Send address changes to Clinical Lymphoma, Myeloma & Leukemia , Elsevier Customer Ser- vice Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA. Submit online: https://www.evise.com/profile/#/CLML/login . Annual subscription rates United States and possessions: individual, $231. All other coun- tries: individual, $256. Orders, claims, and journal inquiries Please contact the Elsevier Customer Service Department near- est you: St. Louis: Elsevier Customer Service Department, 3251 Riverport Lane, Maryland Heights, MO 63043, USA; phone: (800) 654-2452 [toll free within the USA]; (+1) (314) 447- 8871 [outside the USA]; fax: (+1) (314) 447-8029; e-mail: JournalCustomerService-usa@elsevier.com. Oxford: Elsevier Customer Service Department, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK; phone: (+44) (1865) 843434; fax: (+44) (1865) 843970; e-mail: JournalsCus- tomerService EMEA@elsevier.com. Tokyo: Elsevier Customer Service Department, 4F Higashi- Azabu, 1-Chome Bldg, 1-9-15 Higashi-Azabu, Minato-ku, Tokyo 106-0044, Japan; phone: (+81) (3) 5561 5037; fax: (+81) (3) 5561 5047; e-mail: JournalsCustomerServiceJapan@elsevier.com. Singapore: Elsevier Customer Service Department, 3 Killiney Road, #08-01 Winsland House I, Singapore 239519; phone: (+65) 63490222; fax: (+65) 67331510; e-mail: JournalsCustom- erServiceAPAC@elsevier.com. Advertising information: Advertising orders and enquiries can be sent to: USA, Canada and South America: Jaichand Ramsaroop, Advertising Sales Depart- ment, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169, USA; phone: (+1) (212) 633-3690; fax: (+1) (212) 633- 3820; e-mail: j.ramsaroop@elsevier.com. Reprints To order 100 or more reprints for educational, commercial, or promotional use, contact the Commercial Reprints Department, Elsevier Inc., 230 Park Avenue, Suite 800, New York, NY 10169; E-mail: reprints@elsevier.com. Author inquiries For inquiries relating to the submission of articles (including elec- tronic submission where available) please visit this journal’s home- page. You can track accepted articles at http://www.elsevier.com/ trackarticle and set up e-mail alerts to inform you of when an ar- ticle’s status has changed. Also accessible from here is information on copyright, frequently asked questions and more. Contact de- tails for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. Funding body agreements and policies Elsevier has established agreements and developed policies to allow authors whose ar- ticles appear in journals published by Elsevier, to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit http://www.elsevier.com/ fundingbodies . Copyright ©2023 Elsevier Inc. All rights reserved. This journal and the individual contributions contained in it are protected under copyright, and the following terms and conditions apply to their use in addition to the terms of any Creative Commons or other user license that has been applied by the publisher to an individual article: Photocopying Single photocopies of single articles may be made for personal use as allowed by national copyright laws. Permission is not required for photocopying of articles published under the CC BY license nor for photocopying for non-commercial purposes in accordance with any other user license applied by the publisher. Permission of the publisher and payment of a fee is required for all other photocopying, including multiple or system- atic copying, copying for advertising or promotional purposes, resale, and all forms of document delivery. Special rates are available for educational institutions that wish to make photocopies for non-profit educational classroom use. For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 44) 1865 843830 (UK) / ( + 1) 215 239 3804 (USA). Derivative Works Users may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions or companies. Other than for articles published under the CC BY license, permission of the publisher is required for resale or distribution outside the subscribing institution or company. For any subscribed articles or articles published under a CC BY-NC-ND license, permis- sion of the publisher is required for all other derivative works, including compilations and translations. (please consult www.elsevier.com/permissions). Storage or Usage Except as outlined above or as set out in the relevant user license, no part of this pub- lication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Permissions For information on how to seek permission visit www.elsevier.com/permissions or call: ( + 1) 800-523-4069 x 3808 (please consult www.elsevier.com/permissions). Author rights Author(s) may have additional rights in their articles as set out in their agreement with the publisher (more information at http://www.elsevier.com/authorsrights ). Notice Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. To the fullest extent of the law, no responsibility is assumed by the publisher for any injury and/or damage to per- sons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the mate- rial herein. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer. ∞ �The paper used in this publication meets the requirements of ANSI/NISO Z39.48-1992 (Permanence of Paper)
soho.click/2023 Society of Hematologic Oncology Eleventh Annual Meeting September 6–9, 2023 Location: Houston, Texas, USA & Virtual Venue (Hybrid Event) Publication of this abstract supplement is supported by the Society of Hematologic Oncology. Table of Contents Message from the Chairpersons . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S1 Extended Abstracts EXABS-100-AML: What is New in the WHO Classification of AML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S3 Sanam Loghavi, MD EXABS-103-ALL: MRD in Ph+ ALL: How Do You Measure It and What Does It Mean? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S5 Nicholas J. Short, MD EXABS-108-LYM: Treatment Approach to AYA Patients With Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S8 Ann LaCasce, MD, MMSc EXABS-109-LYM: Should We Use Prognostic Indices and/or Biomarkers to Guide Therapy in Follicular Lymphoma? . . . . . . . . . S11 Jessica Okosun, MB BChir PhD EXABS-115-MPN: Current and Emerging Therapies for Systemic Mastocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S14 Prithviraj Bose, MD EXABS-116-MPN: Current and Emergent Therapies for ET . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S18 Kristen Pettit, MD EXABS-119-MDS: An Update on Higher Risk Myelodysplastic Syndromes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S21 Michael J. Hochman, MD, and Amy E. DeZern, MD, MS EXABS-121-MM: MGUS/SMM: Incidence, Evaluation and Follow-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S26 Timothy Schmidt, MD, and Natalie S. Callander, MD EXABS-124-CLL: Covalent Inhibitors of BTK in the Treatment of CLL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S31 Jennifer A. Woyach, MD EXABS-127-CT: Donor Selection in 2023: What is New? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S33 Rohtesh S. Mehta, MD, MPH, MS EXABS-128-CT: GVHD Prevention: What is the New Standard? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S36 Najla El Jurdi, MD, and Shernan Holtan, MD EXABS-131-AML: Can Intervention at MRD Relapse Improve the Outcomes in AML Subsets? . . . . . . . . . . . . . . . . . . . . . . . . . . . S39 Richard Dillon, MD, PhD
EXABS-135-ALL: Development of CAR T-Cells for T-ALL and LBL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S41 Daniil Shmidt, MD, and Maksim Mamonkin, PhD EXABS-136-LYM: Is There Still a Role for CNS Prophylaxis in Large B-Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S43 Adam J. Olszewski, MD EXABS-137-LYM: Circulating Tumor DNA In Lymphoma: When Will It Be Ready for Prime Time? . . . . . . . . . . . . . . . . . . . . . . . S45 Mark Roschewski, MD EXABS-138-LYM: Measuring Physical Function and Tolerability on Treatment in Patients With Hematologic Malignancies . . . . S48 Ajay Major, MD, MBA, Amylou Dueck, PhD, and Gita Thanarajasingam, MD EXABS-139-LYM: Major Advances in the Fight Against Mantle Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S52 Michael Wang, MD EXABS-140-LYM: High Grade B-Cell Lymphoma: Pathologic Classification and Treatment Recommendations . . . . . . . . . . . . . . S54 Brian T. Hill, MD, PhD, and Sarah L. Ondrejka, DO EXABS-141-LYM: DLBCL in Older Adults . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S57 Pallawi Torka, MD EXABS-154-CLL: Biology of Richter’s Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S60 Davide Rossi, MD, PhD EXABS-155-CLL: Standard of Care Therapy of Richter’s Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S61 Deborah M. Stephens, DO EXABS-161-ALL: Updates on Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia S62 Fadi G. Haddad MD, Jayastu Senapati MBBS, MD, Nicholas J. Short MD, Hagop Kantarjian MD, and Elias Jabbour MD EXABS-163-ALL: Approach to Ph-Like Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S65 Ilaria Iacobucci, PhD EXABS-164-ALL: The Role of CNS Prophylaxis in the Era of Contemporary Therapy in Adults With Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S69 Partow Kebriaei, MD EXABS-169-MDS: Update on the Biology of MDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S71 Simona Colla, PhD EXABS-171-MDS: Update on CHIP and CCUS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S73 Lachelle D. Weeks, MD, PhD EXABS-176-AML: Is Acute Myeloid Leukemia With Monocytic Features a Separate Entity? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S75 Daniel A. Pollyea, MD, MS EXABS-178-AML: Venetoclax-Based Triplet Regimens in AML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S77 Curtis Lachowiez, MD, and Courtney DiNardo, MD, MSCE EXABS-181-AML: Achieving Best Response Is Desirable Prior To Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S79 Roland B. Walter, MD, PhD, MS EXABS-182-AML: Familial Predisposition to AML: Prevalence and Implications for Management . . . . . . . . . . . . . . . . . . . . . . . . S81 Lucy A. Godley, MD, PhD EXABS-186-CML: Epigenetic Dysregulation of CML . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S82 S. Tiong Ong, MD EXABS-189-CML: European LeukemiaNet Laboratory Recommendations for the Diagnosis and Management of Chronic Myeloid Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S84 Nicholas C. P. Cross, MA, PhD, FRCPath, Thomas Ernst, MD, and Simona Soverini, PhD EXABS-193-MPN: Choosing and Properly Using a JAK Inhibitor in Myelofibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S86 Colin A. Vale, MD, and Anthony M. Hunter, MD
EXABS-194-MPN: Addressing Anemia in Myelofibrosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S88 Stephen T. Oh, MD, PhD EXABS-198-MM: Frontline Treatment for High-Risk Multiple Myeloma: Personalized? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S89 Saad Usmani, MD, MBA, FACP EXABS-201-MM: Treatment of the Frail Multiple Myeloma Patient: Personalized Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S90 Elizabeth O’Donnell, MD EXABS-206-CLL: Clinical Implications of Monoclonal B-Cell Lymphocytosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S92 Sameer A. Parikh, MBBS EXABS-207-CLL: Is Fixed-Duration Therapy the New Standard of Care in Frontline CLL? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S94 Rodrick Babakhanlou, MD MSc, and Alessandra Ferrajoli, MD EXABS-208-CLL: MRD+ at 1 Year of VenG: Stop Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S96 Othman Al-Sawaf, MD EXABS-209-CLL: The Case for Extending Treatment in MRD+ Patients on Venetoclax + Obinutuzumab Therapy . . . . . . . . . . . . S98 Andrew Lipsky, MD, and Nicole Lamanna, MD EXABS-210-CLL: How a Curative Therapy for CLL Was Developed and Why We Have Stopped Using It . . . . . . . . . . . . . . . . . . S100 John F Seymour, MBBS, FRACP, PhD, Philip A Thompson, MB, BS, and Constantine S Tam, MBBS, MD EXABS-211-CLL: How Biologic Markers Impact Outcomes With Novel Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S102 Talha Munir, PhD EXABS-214-TCL: New Insights Into the Pathogenesis of T-Cell Lymphoma and How This May Guide Treatment . . . . . . . . . . . S105 Laurence de Leval, MD, PhD, and Bettina Bisig, MD, PhD EXABS-215-TCL:TailoringTherapyinPTCL.................................................................. S107 Jasmine Zain, MD EXABS-217-TCL: Novel Targeted Agents in T-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S108 Alessandro Broccoli, MD, PhD, and Pier Luigi Zinzani, MD, PhD EXABS-222-IBCL:NovelCombinationsinIndolentLymphoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S110 Paolo Strati, MD EXABS-223-IBCL: Treatment Options for Marginal Zone Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S112 Emanuele Zucca, MD EXABS-225-PLENIII: Emerging BCL2 Inhibitors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S115 Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD EXABS-230-ABCL: Treatment Options for Primary Mediastinal B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S118 Kieron Dunleavy, MD EXABS-231-ABCL: The Treatment of Primary and Secondary CNS Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S119 Jahanzaib Khwaja, MD, FRCPath, and Kate Cwynarski, MBBS, PhD, FRCP, FRCPath EXABS-233-MCL: Is Stem Cell Transplantation Still Necessary in Mantle Cell Lymphoma? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S123 Timothy S. Fenske, MD EXABS-235-MCL: CAR T-Cell Therapy and Bispecific Antibodies in Mantle Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . S124 Avyakta Kallam, MD, Alexey Danilov, MD, PhD, and Tycel J. Phillips, MD EXABS-239-HL: Treatment of Hodgkin Lymphoma in Older Patients . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S126 Jonathan W. Friedberg MD EXABS-241-LYM: Harnessing the Immune System in Patients With Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S128 Stephen M. Ansell, MD, PhD
EXABS-242-CT: The Continued and Often Underappreciated Benefits of Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma (NDMM) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S130 Natalie S. Callander, MD EXABS-243-CT: Late/Deferred ASCT in Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S134 Clifton C. Mo, MD, Monique A. Hartley-Brown, MD, Shonali Midha, MD, and Paul G. Richardson, MD EXABS-244-CT: Should Patients with AML and Active Disease be Transplanted? . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S137 Boglarka Gyurkocza, MD EXABS-245-CT: Allogeneic Transplantation for AML Patients Without Morphological Remission: Current Challenges and Evolving Solutions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S139 Edmund K. Waller, MD, PhD EXABS-248-NQ-AML:NextQuestions:AcuteMyeloidLeukemia. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S141 Farhad Ravandi, MD EXABS-249-NQ-CT: Next Questions: Cellular Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S142 Nathan Denlinger, DO, MS, and Marcos de Lima, MD Oral Abstracts Oral Abstract Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S145 Poster Presentations Poster Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S149 Submitted Abstracts Acute Lymphoblastic Leukemia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S236 AcuteMyeloidLeukemia................................................................................... S259 ChronicLymphocyticLeukemia............................................................................. S319 ChronicMyeloidLeukemia................................................................................. S331 MyelodysplasticNeoplasms................................................................................. S351 MyeloproliferativeNeoplasms............................................................................... S378 Hodgkin Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S406 Aggressive B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S414 Indolent B-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S446 MantleCellLymphoma.................................................................................... S457 T-Cell Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S464 Multiple Myeloma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S471 Cellular Therapy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S514 Indices Author Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S539 Subject Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . S566
PEACE, LOVE AND HYPOTHESIS The world needs your research. You need Scopus. With up to 230% more coverage of published research worldwide, 16 million author profiles, daily content updates and more – your next big discovery starts with Scopus. For more information visit elsevier.com/Scopus
Message from the Chairpersons On behalf of the organizing committees, it is our pleasure to welcome you to the eleventh annual meeting of the Society of Hematologic Oncology (SOHO). As many of you know, SOHO was established in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies. Since that time, SOHO has grown from a membership base of 400 to more than 7,000 in 2023. Organized by its founders and world class committees, SOHO is the only society specific to this field. During this 3.5-day event, we will participate in a number of educational sessions including in-person didactic lectures, meet-the-professor sessions, debates, plenary sessions, poster presentations, oral abstract presentations and other interactive exchanges and informal engagement experiences. As a hybrid event, all SOHO 2023 general sessions will be available for live and post-session viewing on the virtual platform. The theme of SOHO 2023 is “Progress in Personalized Therapy” as it relates to the field of hematologic oncology. Topics will include Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Hodgkin Lymphoma, T-Cell Lymphoma, Mantle Cell Lymphoma, Aggressive B-Cell Lymphoma, Indolent B-Cell Lymphoma, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Multiple Myeloma and Cellular Therapy. We hope you will find the meeting productive, informative and enjoyable. We would like to thank all SOHO members, attendees and industry partners whose contributions and participation have been essential to the success of the society. With warmest regards, Jennifer Brown, MD, PhD President & Chair, SOHO Worthington & Margaret Collette Professor of Medicine in the Field of Hematologic Oncology Harvard Medical School Director, CLL Center & Institute Physician Dana-Farber Cancer Institute Hagop Kantarjian, MD Secretary, SOHO Professor and Chair Department of Leukemia The University of Texas MD Anderson Cancer Center S1
Mendeley Institutional Edition is the enterprise edition of Elsevier’s leading workflow tool with which 6+ million registered users engage to manage their research references, measure performance of their publications, showcase their work, stay up to date on research trends and discoveries, store datasets and find opportunities with the insights and management capabilities that Institutions need to help researchers progress their research achieve their and the institution’s goals. Trusted and used buy 600+ institutions worldwide www.elsevier.com/ solutions/mendeley Mendeley Institutional Edition
S3 EXABS-100-AML What is New in the WHO Classification of AML Sanam Loghavi, MD1,* 1MD Anderson Cancer Center, Department of Hematopathology, 1515 Holcombe Blvd, Houston, TX, 77027, USA *Corresponding author: sloghavi@mdanderson.org Keywords Classification, AML, WHO, ICC, molecular Introduction The 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours1 provides a hierarchically-driven catalogue of hematologic neoplasms. The updated classification introduces a series of changes to the classification of acute myeloid leukemias (AML), with emphasis on molecular genetic findings, expanding the category of “acute myeloid leukemias with defining genetic abnormalities”. This presentation will provide a comprehensive overview of the WHO 5th updates in the classification of AML. Results and Conclusions The updated classification of AML places added emphasis on molecular genetic abnormalities. The category of “acute myeloid leukemias with defining genetic abnormalities” has been expanded and includes those previously recognized in the WHO 2016 including acute promyelocytic leukemia with PML::RARA and the core binding factor AMLs, as well as the introduction of several novel or modified subtypes where the 20% blast requirement for establishing a diagnosis of AML has been eliminated. These include AML with KMT2A rearrangement, MECOM rearrangement, NUP98 rearrangement, and AML with NPM1 mutation. AML with BCR::ABL1 fusion and AML with CEBPA mutation are also recognized in the category of AML with defining genetic Figure 1 WHO 5th ed Classification of Acute Myeloid Leukemia. Adapted from ref1
S4 abnormalities; however a 20% blast threshold is still enforced for these two entities. The definition of AML with CEBPA mutation has been modified to include biallelic CEBPA mutations as well as single mutations located in the basic leucine zipper (bZIP) region of CEBPA. The previously recognized category of AML with myelodysplasia-related changes has now been renamed as AMLmyelodysplasia related, and the diagnostic criteria for this category has been modified to eliminate the criterion of morphologic dysplasia in isolation as a qualifier and instead to include myelodysplasia-related mutations in ASXL1, BCOR, EZH2, SF3B, SRSF2, U2AF1, ZRSR2, and STAG2, as qualifying criteria for this category. Acute erythroid leukemia (AEL; formerly referred to as pure erythroid leukemia in WHO 2016) remains a distinct subtype in the WHO 5th ed. characterized by neoplastic proliferation of erythroid cells with features of maturation arrest and high frequency of biallelic/multihit TP53 alterations. The diagnosis of AEL supersedes AML-MR in the WHO 5th ed classification. The updates to the classification of AML provide refined definitions and diagnostic criteria based on clinicopathologic parameters and molecular genetic findings, with emphasis on therapeutically and/ or prognostically actionable biomarkers. Acknowledgments We thank the authors of the WHO 5th ed, particularly Dr. Joseph Khoury, Dr. Eric Solary, and Dr. Andreas Hochhaus for their leadership and contributions to the field of hematopathology. References 1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022;36:1703–19. https://doi.org/10.1038/ s41375-022-01613-1.
S5 EXABS-103-ALL MRD in Ph+ ALL: How Do You Measure It and What Does It Mean? Nicholas J Short, MD1,* 1The University of Texas MD Anderson Cancer Center *Corresponding author: nshort@mdanderson.org Keywords Philadelphia chromosome, acute lymphoblastic leukemia, BCR::ABL1, measurable residual disease, next-generation sequencing The outcomes of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) have substantially improved over the past decade. This has been driven largely by the use of later-generation BCR::ABL1 tyrosine kinase inhibitors (TKIs) such as ponatinib,1 and more recently, the use of chemotherapyfree combination regimens with blinatumomab plus a TKI.2,3 These newer Ph+ ALL regimens are able to achieve rapid and deep reduction in disease burden, reflected by high rates of early measurable residual disease (MRD) negativity. While it is wellestablished that MRD negativity plays an important prognostic role in Ph+ ALL, the optimal method to assess MRD in this disease and how to use this information therapeutically are still being established. MRD is highly prognostic in ALL, as has been shown in dozens of studies and confirmed in a large meta-analysis.4 In B-cell ALL, blinatumomab achieves high rates of MRD negativity and is approved for the treatment of MRD-positive disease, highlighting the therapeutic importance of MRD in ALL.5 Common methods to assess MRD in ALL include multiparameter flow cytometry (usually reserved for Philadelphia chromosome-negative ALL), PCR for immunoglobulin (IG) or T-cell receptor (TR) gene rearrangements (used in some European countries but not in the United States), PCR for BCR::ABL1 (for patients with Ph+ ALL), and, more recently next-generation sequencing (NGS) for IG/TR.6 Several studies have shown that achievement of a complete molecular response (CMR), i.e. absence of detectable and/or quantifiable BCR::ABL1 transcripts by PCR, is associated with superior outcomes in Ph+ ALL. In one study of 85 patients with Ph+ ALL treated with hyper-CVAD plus a TKI who did not undergo allogeneic stem cell transplantation (SCT) in first remission, patients who achieved a CMR by 3 months had a 4-year overall survival (OS) rate of 66% versus 36% for those with lesser responses (P=0.0009).7 Importantly, achievement of CMR at 3 months was the only variable that was prognostic for OS on a multivariate analysis. In a subsequent analysis of 84 patients who achieved CMR at 3 months with frontline therapy, patients who received ponatinib had superior survival compared with those who received first- or second-generation TKIs (5-year OS 84% versus 60–65%, respectively).8 This analysis suggests that not only is the depth of response important in Ph+ ALL but also the therapy used to achieve this response. Although historically Ph+ ALL was considered a poor-risk subtype of leukemia that required intensive chemotherapy and allogeneic SCT for all eligible patients, relatively favorable outcomes can now be achieved in patients who do not undergo SCT in first remission, particularly when optimal frontline therapy is given using a potent TKI such as ponatinib. In a subgroup analysis of a study of hyperCVAD plus ponatinib for patients with newly diagnosed Ph+ ALL, patients who achieved a CMR and did not undergo SCT in first remission had a 6-year OS rate of 87% in a landmark analysis.9 A recent retrospective, propensity score analysis of patients with Ph+ ALL who achieved CMR within 3 months showed that while allogeneic SCT was associated with a lower risk of relapse, this was counterbalanced by a higher risk of non-relapse mortality; allogeneic SCT therefore did not have a significant impact on either relapse-free survival or OS.10 These studies highlight the emerging data suggesting that allogeneic SCT can be safely deferred for most patients with Ph+ ALL treated in the modern era. While PCR for BCR::ABL1 has historically been used to assess MRD in Ph+ ALL, PCR or NGS for IG/TR may be more sensitive and specific for MRD in this ALL subtype. Several studies have reported discordance between MRD assessed by PCR for BCR::ABL1 and by PCR or NGS for IG/TR, most commonly in the context of detectable BCR::ABL1 by PCR but MRD negativity by assays for IG/TR rearrangements.11–14 This phenomenon has been described in both p190 and p210 BCR::ABL1 transcripts, although may be more common in those with p190 Ph+ ALL, thus distinguishing it from chronic myeloid leukemia (CML) in lymphoid blast phase. In one study, 23% of children with Ph+ ALL had detectable BCR::ABL1 by PCR but were MRD negative by PCR for IG/TR.12 Cell sorting assays showed that in concordant cases (i.e. those that were MRD positive by both PCR assays), only the ALL blasts had detectable BCR::ABL1. However, in discordant cases, the BCR::ABL1 transcripts were detectable in the non-blast population, representing a “CML-like” biology distinct from both typical Ph+ ALL and CML in lymphoid blast phase. While more data are needed, initial data suggest that the long-term survival of these two entities is similar.13
S6 More recently, NGS-based MRD for IG/TR has been increasingly used in clinical practice for prognostication in ALL. This MRD assay can achieve sensitivity of 1×10–6 (1- to 2-logs deeper than standard flow cytometry or PCR assays) and can further risk stratify patients with ALL.15–17 Most studies using this assay have been conducted in patients with Philadelphia chromosome-negative ALL, where the NGS MRD assay has consistently outperformed conventional flow cytometry assays, though data in Ph+ ALL are relatively scant. In one retrospective analysis of patients with Ph+ ALL, MRD assessed by PCR for BCR::ABL1 and NGS for IG/TR were compared.14 Approximately 1/3 of patients had discordance between these two assays, and overall 15-30% of patients who achieved MRD negativity by the NGS MRD assay still had persistent low-level detectable BCR::ABL1 by PCR. Importantly, among those who were MRD-negative by the NGS assay, PCR for BCR::ABL1 did not impact outcomes, and the 5-year OS for patients who were MRD-positive by PCR but MRD-negative by NGS was 94%. Thus, NGS MRD appears to identify patients with low-level detectable BCR::ABL1 who have a very low risk of relapse and who are unlikely to benefit from additional therapeutic interventions. Further studies are needed to validate these findings and to inform how to use both PCR for BCR::ABL1 and NGS for IG/TR in the management of patients with Ph+ ALL. Assessment of MRD is a fundamental component of ALL therapy, both informing prognosis and guiding therapeutic decisionmaking. With more potent TKI combinations, high rates of MRD negativity can be achieved in Ph+ ALL. These advances have transformed Ph+ ALL from one of the deadliest subtypes of ALL to one that can now be treated with chemotherapy-free regimens and without the need for allogeneic SCT for patients who rapidly achieve MRD negativity. While significant progress has been made in the field of Ph+ ALL, several questions remain regarding how to use MRD information therapeutically in this disease. Early data suggest that NGS-based MRD for IG/TR may outperform conventional PCR for BCR::ABL1, but more studies are needed to confirm these findings. Furthermore, it remains uncertain whether patients with “CML-like” biology (i.e. those who have detectable BCR::ABL1 by PCR despite achieving MRD negativity by other assays) have different outcomes than those with typical Ph+ ALL or whether they should be treated differently. For example, do these non-ALL clones harboring BCR::ABL1 have leukemogenic potential (and thus requiring indefinite TKI therapy)? While it may be reasonable to consider discontinuing TKI therapy in a patient with Ph+ ALL who has achieved long-term CMR, can the same approach be applied to a patient who is NGS MRD negativity at a sensitivity of 10–6 but still has low-level BCR::ABL1 transcripts? Future studies are needed to address these important questions so that we can continue to optimize therapy and cure more patients with Ph+ ALL, while sparing patients the potential toxicity of both allogeneic SCT and long-term TKI therapy. References 1. Jabbour E, Short NJ, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study. The Lancet Haematology 2018;5:e618-e27. 2. Foà R, Bassan R, Vitale A, et al. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. The New England journal of medicine 2020;383:1613-23. 3. Jabbour E, Short NJ, Jain N, et al. Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 2023;10:e24-e34. 4. Berry DA, Zhou S, Higley H, et al. Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia: A Meta-analysis. JAMA Oncol 2017;3:e170580. 5. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 2018;131:1522-31. 6. Short NJ, Jabbour E, Albitar M, et al. Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts. Am J Hematol 2019;94:257-65. 7. Short NJ, Jabbour E, Sasaki K, et al. Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 2016;128:504-7. 8. Sasaki K, Kantarjian HM, Short NJ, et al. Prognostic factors for progression in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia in complete molecular response within 3 months of therapy with tyrosine kinase inhibitors. Cancer 2021;127:2648-56. 9. Kantarjian H, Short NJ, Jain N, et al. Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results. Am J Hematol 2023;98:493-501. 10. Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood 2022;140:2101-12. 11. Cazzaniga G, De Lorenzo P, Alten J, et al. Predictive value of minimal residual disease in Philadelphia-chromosomepositive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica 2018;103:107-15. 12. Hovorkova L, Zaliova M, Venn NC, et al. Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology. Blood 2017;129:2771-81. 13. Zuna J, Hovorkova L, Krotka J, et al. Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease. Leukemia 2022;36:2793-801. 14. Short NJ, Jabbour E, Macaron W, et al. Ultrasensitive
RkJQdWJsaXNoZXIy MTk3NTQxMg==